Kantarjian et al53 assessed the efficacy and security of dasatinib, as when compared with imatinib, for the main-line treatment of CML-CP. Five hundred and nineteen patients with newly diagnosed CML-CP were randomly assigned to receive dasatinib in a dose of a hundred mg once daily (259 patients) or imatinib in https://friedrichs852xof9.wikihearsay.com/user